Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies - PubMed (original) (raw)
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
S Laal et al. J Virol. 1994 Jun.
Abstract
The ability of antibodies to the V3 region and the CD4-binding domain (CD4bd) of human immunodeficiency virus type 1 (HIV-1) to act in synergy to neutralize HIV has been demonstrated previously. However, synergy between antibodies to other HIV-1 epitopes has not been studied. We have used 21 combinations of human monoclonal antibodies (MAbs) directed against different epitopes of the gp120 and gp41 proteins of HIV-1 to evaluate their ability to act in synergy to neutralize HIV-1. Combinations of anti-V3 and anti-CD4bd antibodies, anti-V3 and anti-gp120 C-terminus antibodies, anti-CD4bd and anti-C-terminus antibodies, anti-V3 and anti-gp41 antibodies, and anti-CD4bd and anti-gp41 antibodies were tested. Our results show that some, but not all anti-V3 antibodies can act in synergy with anti-CD4bd antibodies. In addition, for the first time, antibodies to the C-terminus region have been found to act in synergy with the anti-CD4bd antibodies. Various anti-CD4bd MAbs also act in synergy when used together. The use of such cocktails of human MAbs for passive immunization against HIV-1 may prove to be important for therapy in postexposure settings and for prevention of maternal-fetal transmission of the virus. The results also provide information on the types of antibodies that should be elicited by an effective vaccine.
Similar articles
- Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S. Nyambi PN, et al. J Virol. 2000 Aug;74(15):7096-107. doi: 10.1128/jvi.74.15.7096-7107.2000. J Virol. 2000. PMID: 10888650 Free PMC article. - Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F, Nádas A, Gorny MK, Zolla-Pazner S. Verrier F, et al. J Virol. 2001 Oct;75(19):9177-86. doi: 10.1128/JVI.75.19.9177-9186.2001. J Virol. 2001. PMID: 11533181 Free PMC article. - Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, Vlasak J, Xu W, Baba TW, Chenine AL, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Montefiori DC, McClure HM. Ruprecht RM, et al. Transfus Clin Biol. 2001 Aug;8(4):350-8. doi: 10.1016/s1246-7820(01)00187-2. Transfus Clin Biol. 2001. PMID: 11642027 Review. - [Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis].
Vieillard V, Debré P. Vieillard V, et al. Biol Aujourdhui. 2015;209(2):161-6. doi: 10.1051/jbio/2015019. Epub 2015 Oct 29. Biol Aujourdhui. 2015. PMID: 26514385 Review. French.
Cited by
- Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
Ringe RP, Colin P, Ozorowski G, Allen JD, Yasmeen A, Seabright GE, Lee JH, Antanasijevic A, Rantalainen K, Ketas T, Moore JP, Ward AB, Crispin M, Klasse PJ. Ringe RP, et al. PLoS Pathog. 2023 Oct 30;19(10):e1011601. doi: 10.1371/journal.ppat.1011601. eCollection 2023 Oct. PLoS Pathog. 2023. PMID: 37903160 Free PMC article. - Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
Both L, Banyard AC, van Dolleweerd C, Wright E, Ma JK, Fooks AR. Both L, et al. Pediatr Pol. 2013 Sep-Oct;88(5):T15-T23. doi: 10.1016/j.pepo.2013.08.006. Epub 2013 Aug 23. Pediatr Pol. 2013. PMID: 32287402 Free PMC article. Review. - Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ. Howell KA, et al. Cell Rep. 2017 Apr 11;19(2):413-424. doi: 10.1016/j.celrep.2017.03.049. Cell Rep. 2017. PMID: 28402862 Free PMC article. - Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.
Klasse PJ. Klasse PJ. Adv Biol. 2014;2014:157895. doi: 10.1155/2014/157895. Epub 2014 Sep 9. Adv Biol. 2014. PMID: 27099867 Free PMC article.
References
- AIDS Res Hum Retroviruses. 1987 Fall;3(3):283-302 - PubMed
- J Gen Virol. 1987 Jul;68 ( Pt 7):2007-12 - PubMed
- Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 - PubMed
- Virology. 1988 Jun;164(2):362-72 - PubMed
- Nature. 1991 Aug 1;352(6334):436-8 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials